Payer snubs PTC’s Emflaza, signaling pricing trouble ahead of launch – FiercePharma

Washington State continues to battle for lower cost prescriptions. This is your government in action. It’s a good thing.

As Washington State’s HCA noted, PTC Therapeutics has not announced its new price. But the group published a report (PDF) stating that prednisone—at a cost of 5 cents per tablet and $55 per year—will be its preferred corticosteroid for DMD patients. It’s the “lower cost, equally effective” option, according to HCA.

Read the whole story here:

http://www.fiercepharma.com/pharma/policy-report-washington-s-largest-healthcare-purchaser-snubs-ptc-s-emflaza